摘要
目的:探讨CCR9和CCL25蛋白在不同卵巢组织中的表达及其与上皮性卵巢癌患者临床病理因素之间的关系。方法:通过组织芯片结合免疫组织化学法检测78例上皮性卵巢癌组织和30例正常卵巢组织中CCR9和CCL25表达水平,结合上皮性卵巢癌病人的临床病理资料,进行统计分析。结果:CCR9和CCL25在上皮性卵巢癌中高表达,在正常卵巢组织中低表达,二者的表达与上皮性卵巢癌的组织类型、患者年龄无显著相关(P>0.05),而与淋巴结转移、组织学分级和临床分期有显著相关(P<0.05);上皮性卵巢癌组织中CCR9与CCL25表达相关(P<0.05)。结论:CCR9和CCL25在上皮性卵巢癌的发生发展中可能起重要作用,二者可能是上皮性卵巢癌治疗的一个潜在的分子靶点。
Objective：To investigate the expressions of CCR9 and CCL25 protein in different ovarian tissues and the relationship between their expression and clinical pathological factors of epithelial ovarian cancer patients.Methods：Tissue microarray and immunohistochemistry were used to detect the expressions of CCR9 and CCL25 in 78 cases of epithelial ovarian cancer and 30 cases of normal ovarian tissues.The relationship between their expression and clinical pathological factors of epithelial ovarian cancer patients was statistically analyzed.Results：The expressions of CCR9 and CCL25 in epithelial ovarian cancer was high,but in normal ovarian tissue their expression was low.The expressions of CCR9 and CCL25 did not correlate with histological type and age of patients （P〉0.05）,while there was a positive correlation between the expressions of CCR9 and CCL25 with lymphnode metastasis,histological grade and clinical stage（P〈0.05）.The expression of CCR9 was associated with that of CCL25（P〈0.05）.Conclusion：CCR9 and CCL25 may play an important role in the development of epithelial ovarian cancer,which may be a potential molecular target for the treatment of epithelial ovarian cancer.
出处
《现代生物医学进展》
CAS
2015年第4期727-730,755,共5页
Progress in Modern Biomedicine
基金
湖南省自然科学基金项目(14JJ7060)
